Application No.: 09/101,672 Attorney Docket No.: 2481.1603-00

IN THE CLAIMS

Please cancel claims 13 and 14.

Please amend claims 12, 20, and 26, as follows:

12. A solid composition comprising:

 $a\ first\ component\ comprising\ 5-methyl-4'-trifluoromethyl-4-isoxazole carboxanilide;$

a second component comprising a compound of formula I

$$NC \longrightarrow C \longrightarrow C \longrightarrow CF_3$$
 CH_3
 (I)

or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.8% to about 15% of the first component.

 D^2

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com 20. A method of treating an immunological disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising

a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I

Application No.: 09/101,672 Attorney Docket No.: 2481.1603-00

$$NC \longrightarrow C \longrightarrow C \longrightarrow CF_3$$

or a sterioisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.8% to about 15% of the first component.



A method of treating a disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide; a second component comprising a compound of formula I

$$NC \longrightarrow C \longrightarrow CH_3$$

or a sterioisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I;and

a third component comprising a pharmaceutically tolerated excipient;

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 l Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com